Page 2 - Hamlet Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

This press release or the merger does not constitute an offer, either directly or indirectly in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States, or in any other jurisdiction where such offer under the laws and regulations of such relevant jurisdiction would be prohibited by applicable law. Shareholders who are not resident in Sweden and who wish to accept the proposed merger consideration must carry out closer investigations regarding the applicable legislation and possible tax consequences. The two pharmaceutical companies Hamlet Ph...

Hamlet Pharma, listed on Spotlight Stock Market, was awarded an EIC Accelerator grant of 2.2 M EURO in the highly competitive Horizon 2020 program. The EIC accelerator program supports individual small and medium enterprises, in particular start ups and spin out companies, to develop and scale up game changing innovations. At the end of January 2023, Hamlet Pharma filed the final report of the work supported by this grant.

Opening remarks During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H and its collaboration with Linnane Pharma, to define the potential of BAMLET as a drug candidate.

/PRNewswire/ -- DelveInsight's 'Bladder Cancer Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

/PRNewswire/ -- The "Global Bladder Cancer Drug Market (2021-2026) by Type, Treatment, Malignant Potential, Distribution, Geography, Competitive Analysis and...